Paraneoplastic sensorimotor polyneuropathy in prostatic adenocarcinoma

Abstract

Rationale:Paraneoplastic syndrome is a very rare syndrome among prostate cancer patients. In particular, paraneoplastic sensorimotor neuropathy has never been reported as a complication of prostatic adenocarcinoma.Patient concerns:A 75-year-old man who was diagnosed with prostatic adenocarcinoma with multiple metastases received cancer treatment. But, numbness and tingling sensations in both sides of the upper and lower limbs got progressively worse.Diagnosese:He was diagnosed with positive anti-Hu antibodies paraneoplastic sensorimotor polyneuropathy caused by prostatic adenocarcinoma.Interventions:The patient received physical therapy, occupational therapy, and opioid medication during 3 weeks at cancer rehabilitation department during 3 weeks.Outcomes:There was no improvement in functional outcome in this patient. But, the patient's neuropathic pain was improved by the use of opioid agents.Lessons:This case report is the first to report anti-Hu antibody-positive paraneoplastic sensorimotor neuropathy in a patient with adenocarcinoma of the prostate.

Imaging Review of Paraneoplastic Neurologic Syndromes

“…24 As examples, paraneoplastic syndromes associated with Hodgkin lymphoma and prostate cancer causing motor and sensory deficits were recently reported. [25][26][27] Autonomic dysfunction was also previously reported from a syndrome related to a carcinoid tumor. 28 Reports of imaging findings of paraneoplastic polyneuropathy involvement are scarce.…”

A Case of Localized Prostate Cancer Associated with Polymyalgia Rheumatica with Marked Symptomatic Improvement after Robot-Assisted Radical Prostatectomy

“…PNS-related symptoms have an impact on several body systems, including the hematological, cutaneous, vascular, and neurological systems [14]. Although the exact cause of PNS in PCa remains unknown, most hypotheses suggest that inappropriate release of peptide hormones, biologic amines, or growth factors is the primary cause [15]. PNS caused by antibody production, aberrant hormone release, or abnormal cytokine is more frequently diagnosed in patients with prostate cancer, which contains small-cell carcinoma components than those of adenocarcinoma [15].…”

“…Although the exact cause of PNS in PCa remains unknown, most hypotheses suggest that inappropriate release of peptide hormones, biologic amines, or growth factors is the primary cause [15]. PNS caused by antibody production, aberrant hormone release, or abnormal cytokine is more frequently diagnosed in patients with prostate cancer, which contains small-cell carcinoma components than those of adenocarcinoma [15]. Nguyan et al reported that interleukin-6 (IL-6) is a key mediator in several stages of the PCa pathogenesis, including initiation of prostate tumorigenesis, stimulation of tumor growth, induction of aggressive PCa phenotype, PCa progression to the castration-resistant state, promotion of tumor metastasis, and resistance to chemotherapy [16].…”